Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 9/20 | 0.51 |
| ▸ | WNT3A | P56704 | 9/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401715 | 0.86 | LMNA (0.49) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL8489375 | 0.83 | LMNA (0.56) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL8439499 | 0.80 | LMNA (0.53) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL31475594 | 0.79 | LMNA (0.56) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL2494518 | 0.79 | LMNA (0.56) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL3474396 | 0.79 | LMNA (0.56) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL8489219 | 0.79 | LMNA (0.45) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL45490 | 0.79 | LMNA (0.59) | LMNAGAA | |
| SCHEMBL29410857 | 0.79 | CTNNB1 (0.57) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL1950901 | 0.79 | CTNNB1 (0.57) | LMNAGAACTNNB1WNT3AKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6410757-B1 | TAXANE COMPOUNDS | BIO RESEARCH CORPORATION OF YOKOHAMA (JP) | 2002-06-25 | — | — | US | claimed |
| WO-2024215863-A2 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-3148972-B1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9682938-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-3148972-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015183839-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2010-11-04 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1910359-B1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | disclosed |
| EP-1910359-A1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| EP-1851204-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SmithKline Beecham Corporation (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007009911-A1 | PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-01-25 | — | — | US | disclosed |
| WO-2006091592-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1029857-B1 | Baccatin derivatives and a process for producing the same | BIO RES CORP OF YOKOHAMA (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-6410757-B1 | TAXANE COMPOUNDS | BIO RESEARCH CORPORATION OF YOKOHAMA (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1029857-A1 | Baccatin derivatives and a process for producing the same | Bio Research Corporation of Yokohama (JP) | 2000-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | LMNA 3047/4885GAA 1712/4885CTNNB1 664/4885 |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | LMNA 2480/4885GAA 1354/4885CTNNB1 3785/4885 |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | PTPRF, PTPN1, PTPRCAP | LMNA 4736/4885GAA 226/4885CTNNB1 2561/4885 |
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PTPRF, PTPN1, PTPRCAP | LMNA 4736/4885GAA 226/4885CTNNB1 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.